Corbus Pharmaceuticals Holdings Inc (OQ:CRBP)

Business Focus: Bio Therapeutic Drugs

Apr 02, 2024 08:00 am ET

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701...

Mar 12, 2024 08:00 am ET

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and...

Mar 06, 2024 08:00 am ET

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit...

Feb 28, 2024 08:00 am ET

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer...

Feb 06, 2024 09:50 am ET

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the...

Feb 02, 2024 04:01 pm ET

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the closing of its public offering of 4,973,750 shares of its common stock, including...

Jan 31, 2024 09:19 am ET

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a...

Jan 30, 2024 06:55 pm ET

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to...

Jan 26, 2024 07:30 am ET

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner CSPC...

Jan 23, 2024 08:00 am ET

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (CRB-701) has been released, and the corresponding up-to-date data...

Jan 09, 2024 08:00 am ET

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug...

Dec 18, 2023 08:00 am ET

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried...

Nov 07, 2023 08:00 am ET

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 02, 2023 08:00 am ET

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody were presented as...

Oct 17, 2023 08:00 am ET

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for...

Oct 16, 2023 08:00 am ET

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate (ADC)...

Oct 03, 2023 08:00 am ET

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug...

Sep 27, 2023 09:05 am ET

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

NORWOOD, Mass., Sept. 27, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody has been accepted for presentation as a poster at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be in San Diego, CA November 1-5, 2023.

Sep 19, 2023 08:00 am ET

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NORWOOD, Mass., Sept. 19, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held in Boston, MA October 11-15, 2023.

Jul 31, 2023 08:00 am ET

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

NORWOOD, Mass., July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.

Jun 26, 2023 08:00 am ET

Corbus Pharmaceuticals Set to Join Russell Microcap® Index

NORWOOD, Mass., June 26, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today, as part of the 2023 Russell indexes reconstitution.

May 31, 2023 08:00 am ET

Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

NORWOOD, Mass., May 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023. Management will also be available for one-on-one investor meetings during the conference.

May 09, 2023 08:00 am ET

Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical GroupCRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China Presented latest CRB-601 anti-αvβ8 mAb pre-clinical data at American Association of Cancer Research (AACR) 2023 annual meeting with IND submission on track for the second half of 2023Expanded Board of Directors with appointment of Yong Ben, MD NORWOOD, Mass., May 9, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("

May 01, 2023 08:00 am ET

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting

NORWOOD, Mass., May 1, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences' 2023 Frontiers in Cancer Immunotherapy meeting, taking place in New York, NY May 2-4, 2023.

Apr 18, 2023 08:00 am ET

Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target

First in the series to occur on Tuesday, April 25, 2023 at 11:00 AM ET

Apr 17, 2023 08:30 am ET

Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting

CRB-601 shows dose-dependent antitumor activity correlating with increased binding to αvβ8 in pre-clinical tumor modelsCRB-601 enhances anti-PD-1 immunotherapy efficacy and induces long-lasting tumor-specific cytotoxic T-cellsIND submission for CRB-601 on track for 2H 2023NORWOOD, Mass., April 17, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (A

Mar 17, 2023 08:34 am ET

Thinking about buying stock in Corbus Pharmaceuticals, Marathon Digital, Riot Platforms, CleanSpark, or BigBear.ai?

NEW YORK, March 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRBP, MARA, RIOT, CLSK, and BBAI.

Mar 14, 2023 04:35 pm ET

Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting

NORWOOD, Mass., March 14, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for presentation at a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, to be held April 14-19, 2023 in Orlando, Fl.

Feb 13, 2023 05:55 am ET

Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)

CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumorsClinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid tumors potentially including lung, breast and prostate cancer Licensing agreement with CSPC Pharmaceutical Group grants exclusive development and commercialization rights in the United States, Canada, Europe and AustraliaA reverse stock split of 1:30 will be carried out in conjunction with this deal effective on February 14, 2023NORWOOD, Mass., Feb. 13, 2023 /PRNewswire/ --

Nov 30, 2022 09:46 am ET

Thinking about buying stock in Nio, Kalera, Salesforce, Corbus Pharmaceuticals, or Full Truck Alliance?

NEW YORK, Nov. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, KAL, CRM, CRBP, and YMM.

Nov 10, 2022 08:05 am ET

Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of latent TGFβ selectively within the tumor microenvironmentCRB-601 significantly inhibits tumor growth as a single agent and enhances the efficacy of anti-PD-1 immunotherapy in checkpoint inhibitor (CPI) sensitive and CPI-resistant tumor modelsData indicate that anti-tumor activity of CRB-601 as a monotherapy correlates with protein expression of αvβ8CRB-601 is on schedule for IND submission in mid-2023 in solid tumor cancersNORWOOD, Mass., Nov. 10, 2022 /PRNewswire/ -- Corbus Pharmaceu

Nov 08, 2022 07:05 am ET

Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Latest pre-clinical data for CRB-601 monotherapy and in combination with anti-PD1 therapy to be presented this Thursday at SITC 2022IND submission for CRB-601 is on track for mid-2023 Expanding oncology pipeline through strategic transactions remains key priorityCash and investments on hand of $67 million funds operations through the second quarter of 2024NORWOOD, Mass., Nov. 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, today provided a corporate update and reported financial results for the third quarter of 20

Oct 14, 2022 08:05 am ET

Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

NORWOOD, Mass., Oct. 14, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced a poster presentation at the SITC 2022 Annual Meeting being held November 8-12, 2022. The poster will share the updated preclinical validation of the drug candidate CRB-601.

Sep 26, 2022 10:55 am ET

Thinking about buying stock in Aditxt, RedHill Biopharma, Corbus Pharmaceuticals, Li Auto, or Kiora Pharmaceuticals?

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADTX, RDHL, CRBP, LI, and KPRX.

Sep 26, 2022 08:05 am ET

Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

NORWOOD, Mass., Sept. 26, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.

Sep 22, 2022 08:00 am ET

Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference

CRB-913 is a novel oral cannabinoid type 1 receptor (CB1) inverse agonist with potent pre-clinical anti-obesity activityCRB-913 markedly enhances pre-clinical efficacy of liraglutide, semaglutide, and tirzepatide CB1 inverse agonism is a clinically validated therapeutic approach to treating obesityNORWOOD, Mass., Sept. 22, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that preclinical data for CRB-913 are being presented today in an oral presentation at the European Association for the Study of Diabetes

Sep 12, 2022 07:00 am ET

Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

NORWOOD, Mass., Sept. 12, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will take place September 12-14, 2022.

Aug 09, 2022 08:00 am ET

Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on track for mid-2023 Expanding immuno-oncology pipeline through strategic transactions remains key priorityCash and investments on hand of $74 million funds operations into the first quarter of 2024NORWOOD, Mass., Aug. 9, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarte

May 11, 2022 08:00 am ET

Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference

CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironmentAdditional non-clinical data demonstrates combination benefit across a diverse range of syngeneic models with differential sensitivity to checkpoint inhibition Anti-tumor activity correlates with increases in proliferating CD4+ and CD8+ T-cells as well as the NK cell population and a shift towards M1 macrophage polarization, supporting the hypothesis the CRB-601 may overcome immune cell exclusionNORWOOD, Mass., May 11, 2022 /PRNewswire/ -

May 10, 2022 08:00 am ET

Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on-track for the first half of 2023Expanding immuno-oncology pipeline through strategic transactions remains key priorityCash and investments on hand of $86.8 million funds operations into the first quarter of 2024NORWOOD, Mass., May 10, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for t

Apr 08, 2022 01:05 pm ET

Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting

NORWOOD, Mass., April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB-601 are being presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting being held from April 8-13, 2022, in New Orleans, LA. CRB-601 is a potent and selective αvb8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment. TGFb is thought to be the only ligand of the αvb8 integrin. Inhibiting its ability to bind

Mar 11, 2022 07:05 am ET

Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

NORWOOD, Mass., March 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.

Mar 08, 2022 07:05 am ET

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates

NORWOOD, Mass., March 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the fourth quarter and year-end of 2021.

Mar 02, 2022 07:00 am ET

Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today...

Jan 12, 2022 10:35 am ET

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

- Access the event and schedule of presenting companies at virtualinvestorco.com -

Dec 07, 2021 07:05 am ET

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

NORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation.

Nov 12, 2021 07:05 am ET

Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

NORWOOD, Mass., Nov. 12, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the third quarter of 2021.

Nov 11, 2021 07:05 am ET

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

NORWOOD, Mass., Nov. 11, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies London Healthcare Conference being held virtually and in person November 16-19, 2021.

Oct 21, 2021 09:30 am ET

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the...

Aug 12, 2021 08:05 am ET

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported financial results for the second quarter of 2021. Corporate updates: Lenabasum: The...

Jun 24, 2021 11:00 am ET

Thinking about buying stock in Aravive, Marin Software, Staffing 360 Solutions, Corbus Pharmaceuticals, or Globalstar?

NEW YORK, June 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARAV, MRIN, STAF, CRBP, and GSAT.

Jun 24, 2021 08:05 am ET

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, today announced topline results from the...

Jun 01, 2021 07:05 am ET

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth...

May 25, 2021 08:05 am ET

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts...

May 19, 2021 09:20 am ET

CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

May 13, 2021 08:05 am ET

Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates

May 11, 2021 08:05 am ET

Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences

Apr 20, 2021 08:05 am ET

Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)

Mar 30, 2021 08:05 am ET

Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Mar 15, 2021 07:05 am ET

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results

Mar 09, 2021 08:05 am ET

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences

Mar 08, 2021 08:05 am ET

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021

Feb 03, 2021 10:00 am ET

Thinking about buying stock in AMC Entertainment, Nokia, Corbus Pharmaceuticals, GameStop, or Microvision?

NEW YORK, Feb. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, NOK, CRBP, GME, and MVIS.

Jan 20, 2021 08:05 am ET

Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases

Jan 19, 2021 07:00 am ET

The Little-Known Tech That Could Transform Healthcare

NEW YORK, Jan. 19, 2021 /PRNewswire/ -- One under-the-radar company looks to be an absolute game-changer for the healthcare industry. That's because, despite "Big Pharma's" massive resources and staggering amounts of spending, no large pharmaceutical company has ever been able to solve the industry's most critical problem. Mentioned in today's commentary includes: Tilray, Inc. (NASDAQ: TLRY), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Aurora Cannabis Inc. (NYSE: ACB), Canopy Growth Corporation (NASDAQ: CGC), Cronos Group Inc. (NASDAQ: CRON).

Dec 21, 2020 07:30 am ET

Thinking about buying stock in Nantkwest, RealPage, Aerojet Rocketdyne, AIM ImmunoTech, or Corbus Pharmaceuticals?

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NK, RP, AJRD, AIM, and CRBP.

Dec 01, 2020 07:30 am ET

Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?

NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT.

Nov 12, 2020 08:05 am ET

Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Nov 10, 2020 07:05 am ET

Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (“ECS”), today reported financial results for the...

Nov 09, 2020 08:05 am ET

Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Nov 03, 2020 08:05 am ET

Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020

Oct 23, 2020 08:05 am ET

Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020

Oct 21, 2020 08:05 am ET

Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020

Oct 08, 2020 08:05 am ET

Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (“ECS”), today announced a restructuring of its...

Oct 06, 2020 07:05 am ET

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Sep 08, 2020 07:05 am ET

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Aug 06, 2020 07:05 am ET

Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates

Aug 05, 2020 09:25 am ET

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Aug 03, 2020 08:05 am ET

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences

Jul 30, 2020 08:05 am ET

Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020

Jul 29, 2020 08:05 am ET

Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital

Jul 08, 2020 08:05 am ET

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the appointment of George...

Jun 29, 2020 08:05 am ET

Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress

Jun 22, 2020 08:05 am ET

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Jun 01, 2020 08:05 am ET

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

May 27, 2020 08:05 am ET

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

May 22, 2020 08:05 am ET

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

May 15, 2020 08:05 am ET

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences

May 11, 2020 07:05 am ET

Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates

May 04, 2020 08:05 am ET

Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020

Apr 30, 2020 04:15 pm ET

Viela Bio Announces Election of Rachelle Jacques to its Board of Directors

Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the election of Rachelle Jacques to its Board of Directors. As a veteran of the biotechnology and...

Apr 29, 2020 08:05 am ET

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the publication of results...

Mar 12, 2020 07:05 am ET

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results

Mar 10, 2020 08:05 am ET

Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

Mar 05, 2020 08:05 am ET

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020

Feb 11, 2020 04:01 pm ET

Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the closing of its public...

Feb 07, 2020 09:02 am ET

Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Feb 06, 2020 04:01 pm ET

Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Dec 09, 2019 08:05 am ET

Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

Nov 18, 2019 08:17 am ET

Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Nov 12, 2019 08:05 am ET

Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London

Nov 11, 2019 08:05 am ET

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Nov 07, 2019 07:05 am ET

Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced its financial results for the...

Nov 04, 2019 08:05 am ET

Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019

Oct 03, 2019 08:05 am ET

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced the presentation of three abstracts at...

Aug 08, 2019 07:05 am ET

Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates

Aug 01, 2019 08:05 am ET

Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019 at 8:30 a.m. ET to discuss operational and financial...

Jul 03, 2019 05:00 pm ET

Horizons ETFs Rebalances Marijuana-Focused ETFs

TORONTO, July 3, 2019 /CNW/ - Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ":TSX), the Horizons US Marijuana Index ETF ("HMUS":NEO) and the Horizons Emerging Marijuana Growers Index ETF ("HMJR":NEO).

Jun 17, 2019 08:05 am ET

Corbus Pharmaceuticals to Host 2019 R&D Day in New York City

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced that it will host a Research & Development Day (R&D Day) for analysts and accredited institutional investors with live video webcast (details below) on...

Jun 12, 2019 08:05 am ET

Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Stu

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced continued favorable safety and durable improvement in efficacy outcomes at 21 months compared to 12 months in open-label extensions (OLE) of lenabasum...

Jun 10, 2019 06:39 pm ET

Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and F

May 29, 2019 08:05 am ET

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval...

May 28, 2019 08:05 am ET

Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the presentation of six abstracts at the European League Against Rheumatism (“EULAR”) 2019 Annual Meeting being held June 12-15, 2019 in Madrid, Spain....

May 15, 2019 08:05 am ET

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May

May 13, 2019 04:25 pm ET

SHAREHOLDER ALERT: CRBP FSNN MWA AAPL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

May 13, 2019 03:00 pm ET

CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

May 13, 2019 09:32 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NIO, CRBP, ARA and NTNX

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

May 10, 2019 03:00 pm ET

Bronstein, Gewirtz & Grossman, LLC Class Action Update: BPI, CRBP & NIO

May 10, 2019 11:40 am ET

DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or “the Company”) (NASDAQ: CRBP) for violations of §§10(b) and 20(a) of the...

May 09, 2019 04:52 pm ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming May 13, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”)...

May 09, 2019 03:35 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Corbus Pharmaceuticals Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline – CRBP

Pomerantz LLP announces that a class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (NASDAQ: CRBP) and certain of its officers. The class action, filed in United States District Court,...

May 09, 2019 09:28 am ET

CLASS ACTION UPDATE for CRCM, CRBP, ARA and MWA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...

May 09, 2019 07:00 am ET

Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced its financial results for the first quarter ended March 31, 2019. The Company also provided an update on its corporate progress, clinical status and...

May 08, 2019 10:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bridgepoint, Corbus, and NIO and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Bridgepoint Education, Inc., Corbus Pharmaceuticals Holdings, Inc., and NIO Inc. Stockholders have until the deadlines listed...

May 08, 2019 06:54 pm ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the May 13, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”)...

May 06, 2019 11:14 am ET

SHAREHOLDER ALERT: CTL BPI CRBP ARA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

May 03, 2019 08:21 pm ET

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to

May 03, 2019 10:30 am ET

CLASS ACTION UPDATE for T, CNDT, CRBP and BSX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

May 02, 2019 10:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., Spectrum Brands Holdings, Inc., Bridgepoint Education, Inc., and Corbus Pharmaceuticals Holdings, Inc....

May 02, 2019 08:03 pm ET

CRBP CLASS ACTION REMINDER: Hagens Berman Reminds Corbus Pharmaceutical Holdings (CRBP) Investors of Securities Class Action, Encourages Investors with $50,000+ Losses to Contact the Firm

Hagens Berman Sobol Shapiro LLP, with 9 offices in 8 cities around the country and 80 attorneys, reminds investors in Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP) of the securities class action, Kempf v. Corbus Pharmaceutical Holdings, Inc....

May 02, 2019 06:49 pm ET

CRBP MAY 13th DEADLINE: Rosen Law Firm Reminds Corbus Pharmaceuticals Holdings, Inc. Investors of Important Deadline in Securities Class Action; Investors with Losses in Excess of $100K are Encouraged

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corbus Pharmaceuticals Holdings, Inc. from November 14, 2016 through February 28, 2019, inclusive (the “Class Period”) of the important May 13, 2019 lead...

May 02, 2019 05:21 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Corbus Pharmaceuticals Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline – CRBP

May 02, 2019 03:00 pm ET

BPI, USX & CRBP Bronstein, Gewirtz & Grossman, LLC Reminder Shareholders of Class Action

May 02, 2019 08:05 am ET

Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the completion of subject enrollment in RESOLVE-1, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of systemic...

May 01, 2019 08:05 am ET

Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019

Apr 26, 2019 03:25 pm ET

CRBP ALERT: Zhang Investor Law Reminds Investors of May 13 Deadline in Securities Class Action Lawsuit Corbus Pharmaceuticals Holdings, Inc. – CRBP

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from November 14, 2016 through February 28, 2019, inclusive. The lawsuit seeks to...

Apr 26, 2019 09:15 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Co

Apr 25, 2019 10:20 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm

Apr 25, 2019 03:00 pm ET

BPI, USX & CRBP Bronstein, Gewirtz & Grossman, LLC Reminder Shareholders of Class Action

Apr 25, 2019 02:27 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Corbus Pharmaceuticals Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline – CRBP

Apr 25, 2019 10:57 am ET

CLASS ACTION UPDATE for CORT, AVEO, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Apr 25, 2019 09:05 am ET

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000

Apr 24, 2019 12:19 pm ET

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to

Apr 23, 2019 05:03 pm ET

UPCOMING DEADLINE REMINDER: Rosen Law Firm Reminds Corbus Pharmaceuticals Holdings, Inc. Investors of Important May 13th Deadline in Securities Class Action– CRBP

Apr 19, 2019 09:23 am ET

CLASS ACTION UPDATE for SPB, USX, CRBP and APYX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Apr 19, 2019 07:00 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm

Apr 18, 2019 03:00 pm ET

BPI, USX & CRBP Bronstein, Gewirtz & Grossman, LLC Reminder Shareholders of Class Action

Apr 18, 2019 08:05 am ET

Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced that following a Type C meeting with the U.S. Food and Drug Administration (FDA), Corbus will change the primary efficacy endpoint of the ongoing...

Apr 17, 2019 09:45 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, HCSG, INGN and CRBP

Apr 16, 2019 05:52 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Corbus Pharmaceuticals Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline – CRBP

Apr 16, 2019 10:12 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BPI, CNDT, CRBP and BA

The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...

Apr 12, 2019 06:39 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm

Apr 11, 2019 03:00 pm ET

BPI, USX & CRBP Bronstein, Gewirtz & Grossman, LLC Reminder Shareholders of Class Action

Apr 11, 2019 02:52 pm ET

CRBP ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Corbus Pharmaceuticals Holdings, Inc. – CRBP

Apr 11, 2019 01:37 pm ET

SHAREHOLDER ALERT: MHLD BRS HCSG CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Apr 10, 2019 10:58 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, BRS, BPI and CRBP

Apr 09, 2019 10:55 am ET

SHAREHOLDER ALERT: CAG USX CRBP NTNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Apr 08, 2019 10:52 am ET

CLASS ACTION UPDATE for VNDA, CTL, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Apr 08, 2019 08:05 am ET

Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques has more than two decades of experience in U.S. and global commercial...

Apr 07, 2019 09:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Corbus Pharmaceuticals Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline – CRBP

Apr 05, 2019 12:18 pm ET

Robbins Arroyo LLP: Corbus Pharmaceutical Holdings, Inc. (CRBP) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and February 28, 2019. Corbus pur

Apr 04, 2019 03:00 pm ET

BPI, USX & CRBP Bronstein, Gewirtz & Grossman, LLC Reminder Shareholders of Class Action

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Apr 04, 2019 06:00 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm

Apr 03, 2019 11:36 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNDA, SYNH, CRBP and NTNX

Apr 03, 2019 07:15 am ET

Investor Expectations to Drive Momentum within The Hain Celestial Group, Allegheny Technologies, The Hanover Insurance Group, Zimmer Biomet, Corbus Pharmaceuticals, and Preformed Line Products — Disco

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Hain Celestial Group, Inc. (NASDAQ:HAIN), Allegheny Technologies...

Apr 02, 2019 06:31 pm ET

CORBUS CLASS ACTION NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. – CRBP

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from November 14, 2016 through February 28, 2019,...

Apr 02, 2019 05:18 pm ET

Hagens Berman Reminds Corbus Pharmaceutical Holdings (CRBP) Investors of May 13, 2019 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP reminds investors in Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP) of the May 13, 2019 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired Corbus...

Apr 02, 2019 03:31 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of T, CRBP, MBT and ARA

Apr 02, 2019 02:22 pm ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc.

Apr 01, 2019 04:48 pm ET

SHAREHOLDER ALERT: CORT DPLO CRBP ARA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Apr 01, 2019 02:41 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action against Corbus Pharmaceuticals Holdings, Inc. and Certain Officers – CRBP

Apr 01, 2019 10:48 am ET

CLASS ACTION UPDATE for STMP, VNDA, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Mar 29, 2019 02:29 pm ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc.

Mar 28, 2019 08:14 pm ET

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors (CRBP)

Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (NASDAQ:

Mar 28, 2019 08:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Inogen, Spectrum Brands, Bridgepoint, and Corbus and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Inogen, Inc., and Spectrum Brands Holdings, Inc., Bridgepoint Education, Inc., and Corbus Pharmaceuticals Holdings, Inc....

Mar 28, 2019 04:34 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. – CRBP

Pomerantz LLP is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (NASDAQ: CRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or...

Mar 28, 2019 11:37 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAG, AMRN, SYNH and CRBP

Mar 28, 2019 08:05 am ET

Corbus Pharmaceuticals Provides Management Team Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced several changes to its management team. Mark Tepper, Ph.D., will be transitioning to an external role as Senior Scientific Advisor, effective April 1,...

Mar 27, 2019 05:45 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors (CRBP)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (NASDAQ: CRBP) securities between November 14, 2016 and February 28, 2019, inclusive (the “Class Period”). Corbus investors

Mar 27, 2019 03:00 pm ET

BPI, USX & CRBP Bronstein, Gewirtz & Grossman, LLC Reminder Shareholders of Class Action

Mar 27, 2019 11:20 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VALE, BRS, CNDT and CRBP

Mar 26, 2019 04:02 pm ET

SHAREHOLDER ALERT: STMP VNDA USX CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Mar 25, 2019 10:20 am ET

CLASS ACTION UPDATE for ASTE, CAG, CTL and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Mar 22, 2019 06:25 pm ET

Lifshitz & Miller LLP Announces Investigation of Corbus Pharmaceutical Holdings, Inc., Domino's Pizza, Inc., Eventbrite, Inc., Healthcare Services Group, Inc., Maxar Technologies, Inc., and Micron Tec

NEW YORK, March 22, 2019 /PRNewswire/ --

Mar 21, 2019 04:43 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. – CRBP

Mar 21, 2019 04:35 pm ET

CORBUS INVESTOR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc.; Investors with Over $100K in Losses are Encouraged to Contact t

NEW YORK, March 21, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) from November 14, 2016 through February 28, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Corbus investors under the federal securities laws.

Mar 21, 2019 04:27 pm ET

CORBUS PHARMACEUTICALS HOLDINGS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Co

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (Nasdaq: CRBP) in the United States District Court for...

Mar 21, 2019 03:00 pm ET

Bronstein, Gewirtz & Grossman, LLC Class Action Update: BPI, CRBP & NIO

Mar 21, 2019 10:32 am ET

SHAREHOLDER ALERT: VALE WRCDF NIO CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Mar 19, 2019 06:09 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ASTE, CAG, INGN and CRBP

Mar 19, 2019 10:56 am ET

CLASS ACTION UPDATE for AMRN, CNDT, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Mar 17, 2019 10:03 am ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP

Mar 15, 2019 07:56 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. – CRBP

Mar 15, 2019 11:26 am ET

SHAREHOLDER ALERT: DBVT VALE SVXY CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Mar 15, 2019 09:30 am ET

CRBP CLASS ACTION ALERT: Hagens Berman Alerts Corbus Pharmaceutical Holdings (NASDAQ: CRBP) Investors to May 13, 2019 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP alerts investors in Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP) to the May 13, 2019 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the District of...

Mar 14, 2019 05:47 pm ET

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Corbus Pharmaceuticals Holdings, Inc. investors (“Corbus” or the “Company”) (NASDAQ: CRBP) concerning the Company and its officers’ possible violations of federal securities laws.

Mar 14, 2019 10:35 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, BRS, WTW and CRBP

Mar 13, 2019 05:49 pm ET

EQUITY ALERT: Rosen Law Firm Encourages Corbus Pharmaceuticals Holdings, Inc. Investors with Over $100K in Losses to Contact the Firm – CRBP

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) from November 14, 2016 through February 28, 2019, inclusive (the “Class Period”) of the important May 13, 2019 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Corbus investors under the federal securities laws.

Mar 13, 2019 04:54 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. - CRBP

NEW YORK, March 13, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or the "Company") (NASDAQ: CRBP). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

Mar 13, 2019 03:26 pm ET

You are here

Corbus Pharmaceuticals Holdings Inc (OQ:CRBP)

Business Focus: Bio Therapeutic Drugs